▁Introduction 7.8203125
: 1.9072265625
<0x0A> 6.52734375
B 4.921875
rit 3.140625
ish 0.697265625
▁bi 6.8046875
ote 4.33984375
chn 0.4443359375
ology 0.178955078125
▁company 1.73828125
▁X 7.83984375
Y 4.86328125
Z 0.59375
▁has 2.7421875
▁announced 3.125
▁encourag 8.3125
ing 0.0008587837219238281
▁find 4.484375
ings 0.0003314018249511719
▁from 0.31787109375
▁the 2.37890625
▁final 3.958984375
▁stage 1.8251953125
▁of 0.1640625
▁clin 1.669921875
ical 0.001476287841796875
▁tri 0.1207275390625
als 0.00041937828063964844
▁for 1.080078125
▁its 0.72998046875
▁ground 3.939453125
bre 0.88525390625
aking 8.356571197509766e-05
▁cancer 3.125
▁drug 1.6806640625
. 1.646484375
▁The 1.2861328125
▁drug 1.2265625
, 0.5966796875
▁c 5.2734375
oden 0.047698974609375
amed 0.00010907649993896484
▁T 5.15234375
um 5.7890625
oro 8.3828125
C 5.171875
ure 1.05859375
, 0.2413330078125
▁has 0.978515625
▁demonstrated 3.4140625
▁significant 1.8603515625
▁effic 0.9482421875
acy 0.0007662773132324219
▁and 3.857421875
▁a 3.189453125
▁favor 1.8603515625
able 0.0003464221954345703
▁safety 0.14013671875
▁profile 0.00334930419921875
▁in 0.148681640625
▁tre 1.6591796875
ating 0.00012886524200439453
▁various 2.8125
▁types 0.344970703125
▁of 0.0025539398193359375
▁cancer 0.347412109375
. 0.6142578125
▁However 5.44140625
, 0.0009965896606445312
▁while 5.3984375
▁the 0.533203125
▁news 3.82421875
▁has 1.2216796875
▁generated 3.845703125
▁excitement 0.81591796875
▁and 1.9853515625
▁hope 2.3828125
▁among 0.58203125
▁patients 0.83740234375
, 1.904296875
▁anal 6.4921875
yst 0.0006928443908691406
s 0.0021152496337890625
▁are 1.572265625
▁advis 5.19140625
ing 0.0021381378173828125
▁a 4.97265625
▁measured 3.51953125
▁approach 0.2386474609375
▁when 4.53125
▁evalu 2.4140625
ating 7.724761962890625e-05
▁the 0.17138671875
▁potential 1.1337890625
▁market 3.30078125
▁impact 0.56103515625
▁and 3.880859375
▁long 3.078125
- 0.00426483154296875
term 0.0004267692565917969
▁vi 2.025390625
ability 0.0005803108215332031
▁of 0.0177764892578125
▁the 0.311279296875
▁drug 0.21484375
. 0.0216522216796875
<0x0A> 0.1881103515625
Pos 6.140625
itive 0.0172882080078125
▁results 3.125
▁from 0.359375
▁clin 0.9189453125
ical 0.00026798248291015625
▁tri 0.0335693359375
als 2.6106834411621094e-05
: 0.350830078125
<0x0A> 0.1724853515625
T 3.89453125
um 0.01313018798828125
oro 0.0214691162109375
C 0.0006489753723144531
ure 0.00021219253540039062
' 5.09765625
s 0.0007309913635253906
▁positive 2.75
▁out 4.23828125
comes 0.005489349365234375
▁stem 6.15234375
▁from 0.08245849609375
▁compreh 5.828125
ensive 0.0027008056640625
▁Ph 4.59375
ase 0.0018053054809570312
▁III 0.57666015625
▁clin 0.443603515625
ical 5.936622619628906e-05
▁tri 0.039764404296875
als 1.3232231140136719e-05
, 1.7373046875
▁conducted 2.708984375
▁on 1.8701171875
▁a 2.025390625
▁large 1.2099609375
▁coh 2.650390625
ort 4.601478576660156e-05
▁of 0.00978851318359375
▁patients 0.37060546875
▁across 2.07421875
▁different 2.71875
▁cancer 1.3193359375
▁types 0.1319580078125
. 0.20263671875
▁The 0.341552734375
▁drug 1.578125
▁exhib 4.75390625
ited 0.08416748046875
▁remarkable 2.96484375
▁tum 4.51171875
or 0.0169677734375
▁regression 2.091796875
▁rates 1.4404296875
, 0.763671875
▁showing 6.03125
▁promise 3.58203125
▁as 1.173828125
▁a 0.1279296875
▁potential 0.8251953125
▁break 2.4765625
through 7.2479248046875e-05
▁in 0.78955078125
▁cancer 0.75244140625
▁treatment 0.158203125
. 0.021728515625
▁With 4.546875
▁its 2.4921875
▁unique 3.259765625
▁mechanism 0.2169189453125
▁of 0.00522613525390625
▁action 0.00206756591796875
▁target 3.87890625
ing 0.016754150390625
▁specific 2.044921875
▁cancer 1.7744140625
▁markers 3.63671875
, 0.0968017578125
▁T 0.260986328125
um 0.0001327991485595703
oro 0.004528045654296875
C 0.00035119056701660156
ure 0.00011157989501953125
▁offers 1.873046875
▁a 0.3798828125
▁novel 2.154296875
▁approach 0.366943359375
, 6.2265625
▁differenti 3.142578125
ating 0.01314544677734375
▁it 0.1195068359375
▁from 0.003692626953125
▁conventional 3.544921875
▁ther 1.4990234375
ap 0.0078582763671875
ies 3.933906555175781e-06
▁commonly 7.375
▁used 0.11285400390625
▁today 1.435546875
. 0.02044677734375
<0x0A> 0.12225341796875
E 3.556640625
ffic 1.1357421875
acy 0.0191497802734375
▁and 0.26708984375
▁safety 0.051971435546875
▁profile 0.451171875
: 0.050048828125
<0x0A> 0.017059326171875
Not 5.1015625
ably 0.2056884765625
, 0.0004589557647705078
▁T 0.74169921875
um 0.0001474618911743164
oro 0.0017423629760742188
C 0.0002732276916503906
ure 6.854534149169922e-05
▁demonstrated 2.072265625
▁effic 3.451171875
acy 1.71661376953125e-05
▁across 2.271484375
▁a 1.423828125
▁wide 1.140625
▁range 0.06878662109375
▁of 0.0006418228149414062
▁cancer 0.383056640625
▁types 0.045806884765625
, 0.133544921875
▁including 0.443115234375
▁breast 1.3701171875
, 0.1785888671875
▁lung 0.8095703125
, 0.007171630859375
▁pan 3.27734375
cre 2.8133392333984375e-05
atic 0.16259765625
, 0.039337158203125
▁and 0.1864013671875
▁col 1.0322265625
ore 0.0002359151840209961
ct 0.00033283233642578125
al 2.3365020751953125e-05
▁cancer 1.1591796875
. 0.27001953125
▁Scient 9.578125
ific 1.212890625
▁evidence 2.349609375
▁highlight 5.05859375
s 0.2607421875
▁the 0.48974609375
▁drug 0.137939453125
' 0.0179595947265625
s 0.0001767873764038086
▁ability 2.328125
▁to 0.0008411407470703125
▁in 2.623046875
hib 0.0064849853515625
it 3.24249267578125e-05
▁cancer 1.794921875
▁cell 0.71826171875
▁pro 0.81005859375
l 0.0035247802734375
ifer 2.86102294921875e-06
ation 0.0001062154769897461
▁and 0.88232421875
▁indu 0.96533203125
ce 0.0002543926239013672
▁apo 0.296630859375
pt 1.5497207641601562e-05
osis 0.005496978759765625
▁through 4.671875
▁a 1.978515625
▁series 3.66796875
▁of 0.00028967857360839844
▁well 4.45703125
- 0.0011386871337890625
defined 0.93115234375
▁bi 2.41796875
ological 0.1527099609375
▁path 0.87548828125
ways 0.0008740425109863281
. 0.0941162109375
▁Moreover 2.447265625
, 0.0001590251922607422
▁the 0.9765625
▁side 5.2734375
▁effects 0.274169921875
▁observed 1.9638671875
▁were 1.2998046875
▁relatively 2.40625
▁m 0.3427734375
ild 2.8848648071289062e-05
, 0.544921875
▁present 5.46875
ing 0.005279541015625
▁a 0.4716796875
▁less 5.390625
▁bur 2.658203125
dens 0.00604248046875
ome 1.7404556274414062e-05
▁treatment 0.4287109375
▁option 0.366455078125
▁compared 1.7314453125
▁to 0.0122528076171875
▁current 2.21484375
▁available 4.0625
▁alternatives 2.314453125
. 0.048187255859375
<0x0A> 0.0640869140625
Anal 2.087890625
yst 0.283935546875
s 0.2091064453125
▁remain 3.302734375
▁c 0.203369140625
aut 4.887580871582031e-05
ious 0.025543212890625
: 0.265380859375
<0x0A> 0.01021575927734375
Wh 0.9931640625
ile 0.0002067089080810547
▁the 0.5029296875
▁results 2.275390625
▁are 1.2666015625
▁und 2.78515625
ou 0.2088623046875
bt 0.0005350112915039062
edly 0.0002244710922241211
▁prom 1.2158203125
ising 1.8477439880371094e-05
, 0.03173828125
▁anal 0.54833984375
yst 0.000316619873046875
s 0.0019321441650390625
▁ca 2.4375
ution 0.0003216266632080078
▁against 0.55615234375
▁over 0.60986328125
ly 1.5224609375
▁optim 0.08538818359375
istic 0.0005335807800292969
▁expect 1.529296875
ations 2.0503997802734375e-05
▁at 7.4765625
▁this 0.048919677734375
▁early 1.4658203125
▁stage 0.01342010498046875
. 0.13037109375
▁Exper 5.4921875
ts 0.01105499267578125
▁emphas 2.1796875
ize 0.0037364959716796875
▁the 0.81201171875
▁need 0.478271484375
▁for 0.12158203125
▁additional 2.03125
▁scr 5.49609375
ut 2.944469451904297e-05
iny 0.0176849365234375
▁and 0.90478515625
▁further 2.625
▁validation 2.802734375
▁in 3.201171875
▁larger 0.85009765625
, 1.8896484375
▁more 0.88427734375
▁diverse 0.96875
▁patient 0.54345703125
▁populations 0.2213134765625
▁to 2.19921875
▁determine 2.353515625
▁the 0.363525390625
▁applic 8.4765625
ability 0.00011134147644042969
▁and 1.0205078125
▁market 5.7890625
▁potential 0.5185546875
▁of 0.046875
▁T 0.349853515625
um 0.00015854835510253906
oro 0.00299835205078125
C 0.0003790855407714844
ure 0.00015223026275634766
. 0.10711669921875
▁Tri 7.9765625
als 0.654296875
▁often 5.8359375
▁face 3.361328125
▁un 2.884765625
for 0.56591796875
ese 5.328655242919922e-05
en 0.007274627685546875
▁challeng 0.7490234375
es 2.872943878173828e-05
▁when 5.80078125
▁transition 2.7890625
ing 0.00521087646484375
▁to 1.572265625
▁real 2.3671875
- 0.005207061767578125
world 0.0809326171875
▁settings 0.57275390625
, 0.188232421875
▁highlight 3.06640625
ing 0.00047659873962402344
▁the 0.0301666259765625
▁importance 0.7548828125
▁of 0.001201629638671875
▁rig 2.68359375
orous 0.01519775390625
▁post 3.5390625
- 0.00708770751953125
mark 1.3759765625
eting 0.00023794174194335938
▁studies 2.41015625
▁to 1.0166015625
▁confirm 2.66796875
▁the 0.6875
▁drug 0.326171875
' 0.0088348388671875
s 7.522106170654297e-05
▁long 1.7734375
- 0.0003650188446044922
term 0.0020275115966796875
▁safety 1.41015625
▁and 0.0958251953125
▁effect 1.951171875
iveness 0.0009136199951171875
. 0.06353759765625
<0x0A> 0.064697265625
Reg 3.8359375
ul 0.0274810791015625
atory 0.005191802978515625
▁hur 2.408203125
d 5.125999450683594e-06
les 0.0009784698486328125
▁and 0.6591796875
▁pr 1.5380859375
icing 4.172325134277344e-05
▁concerns 0.89013671875
: 0.00807952880859375
<0x0A> 0.0008473396301269531
M 5.98828125
oving 0.18115234375
▁forward 0.1590576171875
, 0.01526641845703125
▁regul 1.0341796875
atory 0.03369140625
▁appro 0.31689453125
val 3.123283386230469e-05
▁will 1.98828125
▁be 0.47607421875
▁a 0.80517578125
▁critical 1.02734375
▁mil 2.388671875
estone 3.457069396972656e-05
▁for 0.82080078125
▁T 0.62451171875
um 0.00017178058624267578
oro 0.0015668869018554688
C 0.0002149343490600586
ure 0.00011372566223144531
. 1.103515625
▁Any 7.2734375
▁del 2.3671875
ays 5.137920379638672e-05
▁or 0.798828125
▁short 5.93359375
com 0.1854248046875
ings 1.0728836059570312e-06
▁in 0.412353515625
▁the 0.56591796875
▁drug 2.525390625
' 0.3046875
s 1.5735626220703125e-05
▁appro 1.224609375
val 0.0001373291015625
▁process 0.155029296875
▁may 1.59375
▁significantly 2.05859375
▁impact 0.358642578125
▁its 0.46826171875
▁market 1.1220703125
▁entry 3.654296875
▁and 0.53759765625
▁ult 5.796875
imate 5.424022674560547e-05
▁success 1.12109375
. 0.07928466796875
▁Anal 2.953125
yst 0.0014162063598632812
s 0.0010290145874023438
▁also 0.79443359375
▁raise 1.6767578125
▁concerns 0.1544189453125
▁over 1.212890625
▁potential 2.759765625
▁pr 0.429443359375
icing 3.1113624572753906e-05
▁strateg 2.94140625
ies 5.602836608886719e-06
, 0.4560546875
▁as 2.935546875
▁the 1.244140625
▁costs 4.78515625
▁associated 0.9443359375
▁with 0.0012054443359375
▁bi 4.2734375
ote 1.0556640625
chn 0.474365234375
ological 2.119140625
▁break 3.169921875
through 5.6862831115722656e-05
s 0.0103759765625
▁can 1.087890625
▁be 0.7431640625
▁considerable 3.72265625
. 0.415283203125
▁St 6.13671875
rik 0.3603515625
ing 4.208087921142578e-05
▁a 0.68017578125
▁balance 0.09320068359375
▁between 0.01629638671875
▁afford 1.2568359375
ability 0.0509033203125
▁for 5.1953125
▁patients 0.056427001953125
▁and 0.061676025390625
▁ens 7.546875
uring 0.0002187490463256836
▁a 1.453125
▁sust 1.7236328125
ain 0.0032196044921875
able 0.0003921985626220703
▁business 1.1435546875
▁model 0.0269317626953125
▁for 0.99560546875
▁the 0.8330078125
▁company 0.55029296875
▁will 0.50634765625
▁be 0.1795654296875
▁essential 1.8349609375
▁for 1.2001953125
▁the 1.587890625
▁w 4.01953125
ides 2.968311309814453e-05
p 0.0004897117614746094
read 9.59634780883789e-05
▁ad 0.12939453125
option 0.00015795230865478516
▁of 0.2080078125
▁this 2.591796875
▁potentially 2.638671875
▁life 1.21484375
- 4.410743713378906e-05
s 0.2296142578125
aving 8.440017700195312e-05
▁drug 1.25
. 0.007160186767578125
<0x0A> 0.031585693359375
Comp 6.7890625
et 0.0838623046875
itive 1.2548828125
▁landscape 0.1751708984375
▁and 0.1552734375
▁future 1.9208984375
▁directions 3.220703125
: 0.01058197021484375
<0x0A> 0.00044989585876464844
The 1.65625
▁cancer 1.7783203125
▁th 1.810546875
era 2.205371856689453e-05
pe 5.3763389587402344e-05
ut 2.0265579223632812e-06
ics 0.06103515625
▁market 0.2315673828125
▁is 0.251708984375
▁highly 0.51708984375
▁compet 0.05230712890625
itive 2.0623207092285156e-05
, 0.1304931640625
▁with 0.202392578125
▁existing 4.234375
▁treatment 3.7265625
▁options 0.048187255859375
▁already 1.984375
▁approved 5.26953125
▁and 0.92919921875
▁in 1.8994140625
▁use 1.5810546875
. 0.278076171875
▁To 4.11328125
▁pen 7.7578125
et 1.9550323486328125e-05
rate 4.649162292480469e-06
▁this 0.467041015625
▁market 1.013671875
, 0.265869140625
▁X 0.97119140625
Y 0.0003426074981689453
Z 0.0002372264862060547
▁must 1.6572265625
▁establish 3.564453125
▁T 2.1015625
um 0.00011420249938964844
oro 0.0018634796142578125
C 0.00030517578125
ure 0.00011897087097167969
' 0.5400390625
s 6.270408630371094e-05
▁superior 2.65234375
ity 0.137451171875
▁over 1.1494140625
▁established 3.953125
▁ther 1.16015625
ap 0.0005164146423339844
ies 5.364418029785156e-06
. 1.8212890625
▁Furthermore 4.2734375
, 8.690357208251953e-05
▁it 4.02734375
▁will 1.521484375
▁be 1.0771484375
▁cru 1.1787109375
cial 1.1801719665527344e-05
▁to 0.320068359375
▁assess 3.8984375
▁potential 3.078125
▁syn 2.232421875
erg 0.00931549072265625
ies 0.044891357421875
▁with 0.32275390625
▁complement 4.56640625
ary 0.0020580291748046875
▁treat 2.443359375
ments 6.67572021484375e-06
▁or 2.5390625
▁develop 5.671875
▁combin 7.14453125
ational 1.544921875
▁ther 0.491455078125
ap 0.1253662109375
ies 6.198883056640625e-06
▁for 2.900390625
▁improved 2.5234375
▁patient 1.271484375
▁out 0.00988006591796875
comes 2.384185791015625e-06
. 0.0848388671875
▁Coll 6.96875
abor 0.0002808570861816406
ations 0.51953125
▁with 0.1541748046875
▁research 3.828125
▁bodies 6.49609375
, 1.373046875
▁health 1.5224609375
care 0.0673828125
▁institutions 2.220703125
, 0.017822265625
▁and 0.1024169921875
▁ph 1.6923828125
arma 0.0135498046875
ce 0.046661376953125
ut 2.0265579223632812e-06
ical 6.556510925292969e-05
▁companies 0.283447265625
▁could 1.8701171875
▁acceler 3.416015625
ate 9.298324584960938e-06
▁the 0.6044921875
▁drug 0.7587890625
' 0.01084136962890625
s 4.649162292480469e-05
▁development 1.05859375
▁and 0.28857421875
▁enh 3.7578125
ance 2.7060508728027344e-05
▁its 0.08270263671875
▁market 1.5537109375
▁pen 2.861328125
etr 0.0031890869140625
ation 8.952617645263672e-05
. 0.10223388671875
<0x0A> 0.0635986328125
Con 2.41015625
clusion 0.300537109375
: 0.1397705078125
<0x0A> 8.96875
B 5.3203125
rit 2.115234375
ish 0.007175445556640625
▁bi 0.015777587890625
ote 0.0017986297607421875
ch 3.048828125
▁X 2.353515625
Y 0.0014963150024414062
Z 0.0005497932434082031
' 0.71630859375
s 0.0015544891357421875
▁cancer 3.443359375
▁drug 0.325439453125
, 1.349609375
▁T 0.19775390625
um 0.0002205371856689453
oro 0.005306243896484375
C 0.0005736351013183594
ure 0.0004241466522216797
, 0.00643157958984375
▁has 0.9306640625
▁displayed 4.1015625
▁encourag 2.470703125
ing 6.67572021484375e-05
▁results 0.4462890625
▁in 0.70703125
▁Ph 2.150390625
ase 0.00027370452880859375
▁III 0.00799560546875
▁clin 0.224609375
ical 4.017353057861328e-05
▁tri 0.00464630126953125
als 8.344650268554688e-07
, 0.892578125
▁demonstr 2.576171875
ating 2.4437904357910156e-05
▁impress 3.916015625
ive 0.00016772747039794922
▁effic 0.292724609375
acy 1.0609626770019531e-05
▁against 5.375
▁various 0.517578125
▁cancer 0.55712890625
▁types 0.015228271484375
▁with 3.564453125
▁manage 4.16015625
able 5.710124969482422e-05
▁side 0.2261962890625
▁effects 0.00464630126953125
. 0.04254150390625
▁However 1.3486328125
, 0.00013935565948486328
▁anal 0.953125
yst 0.0004048347473144531
s 0.0023937225341796875
▁ur 3.197265625
ge 0.0016660690307617188
▁ca 0.223388671875
ution 2.6464462280273438e-05
, 1.93359375
▁emphas 1.26953125
izing 0.0008978843688964844
▁that 2.6953125
▁further 1.5107421875
▁expl 7.10546875
oration 0.08441162109375
, 2.634765625
▁regul 0.935546875
atory 5.745887756347656e-05
▁appro 0.0850830078125
val 6.210803985595703e-05
, 0.11822509765625
▁and 0.12939453125
▁additional 7.06640625
▁real 4.82421875
- 0.0008101463317871094
world 0.01910400390625
▁evidence 2.0
▁are 0.2244873046875
▁needed 2.1328125
▁before 1.4033203125
▁w 4.42578125
ides 0.00013077259063720703
p 0.0008101463317871094
read 2.6106834411621094e-05
▁implementation 3.560546875
. 0.268798828125
▁Over 4.7578125
coming 2.125
▁regul 1.34765625
atory 6.747245788574219e-05
▁hur 0.344970703125
d 2.7418136596679688e-06
les 2.2649765014648438e-05
, 1.287109375
▁pr 1.783203125
icing 0.00010907649993896484
▁challeng 2.375
es 7.867813110351562e-06
, 0.0071868896484375
▁and 0.028228759765625
▁establish 2.37890625
ing 3.135204315185547e-05
▁different 6.27734375
iation 0.0002734661102294922
▁from 0.473876953125
▁existing 0.59033203125
▁ther 1.0302734375
ap 0.0008101463317871094
ies 1.1324882507324219e-05
▁will 0.416015625
▁determine 3.33203125
▁the 0.58740234375
▁ult 3.607421875
imate 1.1801719665527344e-05
▁success 0.450439453125
▁of 0.107421875
▁T 0.71826171875
um 0.00011706352233886719
oro 0.0024871826171875
C 0.00036072731018066406
ure 0.00012362003326416016
. 0.73193359375
▁Nevertheless 3.12890625
, 0.00010585784912109375
▁the 0.60205078125
▁initial 5.32421875
▁find 0.308837890625
ings 1.1920928955078125e-06
▁offer 1.9814453125
▁hope 0.66064453125
▁for 0.32177734375
▁patients 1.0068359375
, 2.435546875
▁p 5.37109375
aving 0.0021305084228515625
▁the 0.006443023681640625
▁way 0.00521087646484375
▁for 0.03863525390625
▁potential 2.033203125
▁adv 3.248046875
anc 0.2386474609375
ements 1.0132789611816406e-05
▁in 0.025115966796875
▁cancer 0.1553955078125
▁treatment 0.1527099609375
▁and 2.05078125
▁transform 6.9921875
ing 0.12493896484375
▁the 0.45703125
▁lives 0.947265625
▁of 0.0008187294006347656
▁those 1.3603515625
▁affected 0.30029296875
▁by 0.4521484375
▁the 1.55859375
▁disease 0.0849609375
. 0.0166168212890625
